Abstract - Use of Surrogate Markers in Monitoring Disease Modifying Therapy in Multiple Sclerosis
	Because of the protracted and unpredictable clinical course of MS, biological surrogate markers are much needed to make the assessment of disease-modifying treatments more efficient. MRI outcome measures (gadolinium enhancement; T1/T2 abnormalities; progressive, diffuse axonal loss) are now widely used to monitor treatment outcome in MS and may be considered as surrogate markers for clinical relapses. This CME will provide an opportunity for neurologists to understand the use of surrogate markers in the monitoring of disease-modifying therapy.